Another Watertown Biotech Goes Public via Reverse Merger, and a Flurry of Leasing at the Arsenal

Another Watertown Biotech Goes Public via Reverse Merger, and a Flurry of Leasing at the Arsenal

Sam Ghilardi 7/7/26 Sam Ghilardi 7/7/26

Another Watertown Biotech Goes Public via Reverse Merger, and a Flurry of Leasing at the Arsenal

Plus Biolabs expansion and Labshare's new tenants

Another Watertown Biotech Goes Public and the Commonwealth Claws Back Hiring Tax Credits

Sam Ghilardi 6/9/26 Sam Ghilardi 6/9/26

Another Watertown Biotech Goes Public and the Commonwealth Claws Back Hiring Tax Credits

Plus pre-clinical data results and more!

C4's Partnership with Roche, Gilead Options Kymera degrader, and Astellas Licenses Dyno Capsid

Sam Ghilardi 4/14/26 Sam Ghilardi 4/14/26

C4's Partnership with Roche, Gilead Options Kymera degrader, and Astellas Licenses Dyno Capsid

Plus the initial dosing of Enanta and Avencell's Clinical Trials

Sam Ghilardi 1/20/26 Sam Ghilardi 1/20/26

All About Watertown's VC Funding

2025 Funding numbers are in, 2026 early raises, Lyra Therapeutics runs out of time and more